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Chronic graft-versus-host disease (GVHD) induces signiﬁcant morbidity and mortality after allogeneic he-
matopoietic stem cell transplantation. Corticosteroids are standard initial therapy, despite limited efﬁcacy and
long-term toxicity. Based on our experience using bortezomib as effective acute GVHD prophylaxis, we hy-
pothesized that proteasome-inhibition would complement the immunomodulatory effects of corticosteroids
to improve outcomes in chronic GVHD (cGVHD). We undertook a single-arm phase II trial of bortezomib plus
prednisone for initial therapy of cGVHD. Bortezomib was administered at 1.3 mg/m2 i.v. on days 1, 8, 15, and
22 of each 35-day cycle for 3 cycles (15 weeks). Prednisone was dosed at .5 to 1 mg/kg/day, with a suggested
taper after cycle 1. All 22 enrolled participants were evaluable for toxicity; 20 were evaluable for response.
Bortezomib plus prednisone therapy was well tolerated, with 1 occurrence of grade 3 sensory peripheral
neuropathy possibly related to bortezomib. The overall response rate at week 15 in evaluable participants was
80%, including 2 (10%) complete and 14 (70%) partial responses. The organ-speciﬁc complete response rate
was 73% for skin, 53% for liver, 75% for gastrointestinal tract, and 33% for joint, muscle, or fascia involvement.
The median prednisone dose decreased from 50 mg/day to 20 mg/day at week 15 (P < .001). The combination
of bortezomib and prednisone for initial treatment of cGVHD is feasible and well tolerated. We observed a
high response rate to combined bortezomib and prednisone therapy; however, in this single-arm study, we
could not directly measure the impact of bortezomib. Proteasome inhibition may offer beneﬁt in the treat-
ment of cGVHD and should be further evaluated.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION decreases type 1 helper T cell cytokine production, and in-
Chronic graft-versus-host disease (cGVHD) is associated
with signiﬁcant morbidity, decreased quality-of-life, and late
mortality after allogeneic hematopoietic stem cell trans-
plantation (HSCT) [1-3]. Corticosteroids are standard-of-care
for initial cGVHD therapy, despite limited efﬁcacy and sig-
niﬁcant long-term toxicity [4]. Novel cGVHD therapies are a
major unmet need.
Bortezomib is a proteasome-inhibitor that exerts immu-
nomodulatory effects, in part, through inhibition of nuclear
factor-kappa B, a regulator of cytokine signaling and T and
B cell development, activation, differentiation, and survival
[5-11]. Bortezomib depletes proliferating allo-reactive T cells,dgments on page 1742.
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14.06.040hibits antigen presenting cell (APC) function, with limited
impact on the number and function of regulatory T cells
(Tregs), which are important mediators of graft-versus-host
disease (GVHD) control [12-17]. Bortezomib is effective in
preventing acute GVHD in patients undergoing mismatched
unrelated donor reduced-intensity allogeneic HSCT [18,19].
Case reports of bortezomib treatment in patients with
relapsed multiple myeloma after allogeneic HSCT describe
cGVHD responses [20-22]. Prospective trials evaluating bor-
tezomib for cGVHD treatment have not been reported. We
undertook a phase II trial to assess the feasibility and efﬁcacy
of adding bortezomib to corticosteroids for the initial treat-
ment of cGVHD.METHODS
This was a single-arm, single-center, prospective phase II trial to eval-
uate the safety and efﬁcacy of combined bortezomib and prednisone ther-
apy for initial treatment of cGVHD. It was approved by the institutional
review board of the Dana-Farber Cancer Institute/Harvard Cancer Center.Transplantation.
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ClinicalTrials.gov (ClinicalTrials.gov Identiﬁer: NCT00815919).
Cohort Selection
Participants had cGVHD necessitating initiation of systemic therapy.
Recipients of matched or mismatched, related or unrelated allogeneic HSCT
with myeloablative or reduced-intensity conditioning who were nonpreg-
nant, 18 years, and 100 days after transplantation were eligible. Major
exclusion criteria included peripheral neuropathy grade 1 with pain in the
4 weeks prior, active cancer or infection, Eastern Cooperative Oncology
Group performance status >2, active heart failure, cardiac ischemia,
or ventricular arrhythmias, abnormal renal function (serum creatinine
>3 mg/dL or hemodialysis), or severe cytopenias (absolute neutrophil count
<1500/mm3 or platelet count <50,000/mm3). Patients with abnormal liver
function tests (serum total bilirubin >2 mg/dL, serum alanine or aspartate
aminotransferase >2  ULN) were included if hepatic dysfunction was
considered a cGVHD manifestation. Recipients of systemic corticosteroid
therapy within 4 weeks prior to enrollment were not eligible.
Study Treatment
Enrolled subjects received 1.3 mg/m2 bortezomib intravenously on days
1, 8, 15, and 22 of each 35-day cycle for 3 cycles (15 weeks). The dosing
schedule was chosen for its minimal toxicity and effective proteasome-
inhibition in phase I studies and to limit the number of treatment visits
[23]. Concurrently, participants initiated .5 to 1 mg/kg of prednisone daily.
The initial study dose was .5 mg/kg daily, but the study protocol was later
amended to allow a starting dose of up to 1mg/kg daily, per the discretion of
the treating physician. The suggested prednisone taper was 10% to 25% every
1 to 2 weeks after cycle 1. Organ-speciﬁc topical therapies were allowed. No
additions or subtractions of other systemic immunosuppressive medica-
tions were permitted during the 15-week study. In participants receiving
other immunosuppressive medications at enrollment, doses were adjusted
based on the therapeutic range of that medication. Participants received
standard antimicrobial prophylaxis per institutional guidelines.
Study Assessments
Participants were evaluated at enrollment and on days of bortezomib
infusion. Global and organ-speciﬁc cGVHD assessments at involved sites
were performed at baseline and week 15, per National Institutes of Health
(NIH) consensus criteria (see Supplementary Appendix) [24]. Participants
completed a validated neurotoxicity assessment at baseline and week
15 [25].
Laboratory Analysis
Routine laboratory examination and serum cytomegalovirus viral load
assessment were performed weekly during study treatment. Quantitative
immunoglobulin measurement was performed at baseline and week 15, and
immunophenotypic analysis of peripheral blood mononuclear cells were
performed at baseline, week 6, week 11, and at the completion of study
therapy. Treg cells were deﬁned as CD3þCD4þCD25med-highCD127neg-low,
conventional CD4þ T cells as (Tcon) CD3þCD4þCD25neg-lowCD127med-high,
naïve Tregs as CD4þCD25med-highCD127neg-lowCD45RO-, memory Tregs as
CD4þCD25med-highCD127neg-lowCD45ROþ, dendritic cells (DC) as HLA-DRþ
lineage marker negative, myeloid DC as CD11cþ, plasmacytoid DC as
CD123þ, natural killer cells as CD3CD56þ, T cells as CD3þ, and B cells as
CD19þ.
Fifty mL of whole blood (15% EDTA) was incubated with the following
ﬂuorophore-conjugated monoclonal antibodies: anti-CD3 V450 (clone
UCHT1, BD Biosciences, San Jose, CA), anti-CD4 APC-H7 (clone RPA-T4, BD
Biosciences), anti-CD8 Paciﬁc Orange (clone 3B5, Invitrogen, Carlsbad, CA),
anti-CD25 PE-Cy7 (clone M-A251, BD Biosciences), anti-CD127 PE-Cy5
(clone eBioRDR5, eBioscience), anti-CD56 PE (clone B159, BD Biosciences),
anti-CD19 APC (clone HIB19, BD Biosciences), anti-CD11cþ PE-Cy5 (clone B-
ly6, BD Biosciences), and anti-CD123 FITC (clone AC145, Miltenyi, Bergisch
Gladbach, Germany). Red cell lysis with 500 mL of BD PharmLyse lysing so-
lution followed. Cell analysis was performedwith the use of the FACSCanto II
system (BD Biosciences) and FACSDiva software (BD Biosciences).
Study Endpoints
The primary endpoint was the overall response rate at week 15dthe
completion of study treatment. Secondary endpoints included toxicity
assessment, the proportion of patients tolerating 50% steroid dose
reduction at week 15, overall and relapse-free survival (OS, RFS), and the
proportion of patients requiring prednisone at 1 year after completion of
bortezomib treatment. A complete response (CR) was deﬁned as resolution of
all reversible manifestations of cGVHD. Partial response (PR) was deﬁned per
NIH response consensus criteria guidelines [26] as improvement of mani-
festations of cGVHD with clinical evidence of residual cGVHDda decrease1 point on a 0 to 3-point organ-speciﬁc categorical scale or 2 points on a
physician-reported 0 to 10-point global scale (see the Supplementary
Appendix)dwithout progression in any organs or sites. Progressive cGVHD
was deﬁned as an increase of 1 point on an organ-speciﬁc 0 to 3-point
categorical scale or the institution of a new immunosuppressive agent or
any increase in the corticosteroid dose above a participant’s baseline dose
before the completion of study therapy. Stable disease (SD) was deﬁned as no
evidence of cGVHD response without evidence of progressive cGVHD.Mixed
response was deﬁned as a response in primary sites of cGVHD involvement
but interval progressive cGVHD in other organs or sites. Oral or ocular
cGVHD involvement were not evaluated for organ-speciﬁc response and
were not included in global response assessment, as topical therapies were
permitted during the study.
Statistical Analysis
Baseline characteristics were reported descriptively. Pre-to-post-
treatment change in cGVHD score and immunophenotype data were
compared using the Wilcoxon signed-rank test. The initial prednisone dose
between responders and nonresponders were compared using the Wil-
coxon rank-sum test. OS and RFS were calculated using the Kaplan-Meier
method. OS was the start of treatment to death from any cause. Partici-
pants alive or lost to follow-up were censored at the time last seen alive. RFS
was the start of treatment tomalignant disease relapse/progression or death
from any cause, whichever occurred ﬁrst. Participants alive without disease
relapse/progression were censored at the time last seen alive and relapse-
free. Cumulative incidence of nonrelapse mortality (NRM) and relapse
with or without death were constructed reﬂecting time to relapse and time
to nonrelapse death, respectively, as competing risks. Failure-free survival
was the start of treatment to cGVHD progression necessitating additional
systemic therapy, malignant disease relapse/progression or death from any
cause, whichever occurred ﬁrst. All calculations were done using SAS 9.3
(SAS Institute Inc, Cary, NC), and R version 2.13.2 (the CRAN project).
It was prospectively determined that the study treatment would be
considered promising if overall response rate (CR þ PR) was 60% and
unacceptable if  30%. With this design, the probability of concluding the
treatment as promising was .94 if the true but unknown response rate was
60%, but .09 if the true rate was 30%. This decision rule was calculated using
an exact binomial distribution.
RESULTS
Patients
BetweenMarch 2009 and November 2011, 22 participants
with cGVHD were enrolled. Their baseline demographic,
transplantation, and GVHD characteristics are reported in
Table 1. Nineteen participants had de novo cGVHD, whereas 3
had previous grade II to IV acute GVHD. Participants had a
median of 3.5 (range, 1 to 7) sites of baseline cGVHD
involvement. The degree of baseline cGVHD involvement in
each participant by organ is depicted in Figure 1. Three par-
ticipants had only liver involvement, and GVHD was
conﬁrmedbyliverbiopsy ineachcase. Sevenparticipantswith
diagnostic features of cGVHD in an organ other than skin had
erythematous or maculopapular skin GVHD lesions without
other diagnostic or distinctive ﬁndings of skin cGVHD. Eight
participants were on systemic immunosuppressive agents at
onset of cGVHD and continued on these medications. Two
participants developed cGVHD despite having previously
received prophylactic rituximab as part of a clinical trial
evaluating its safety and efﬁcacy in the prevention of cGVHD
(details in Supplementary Tables A and B). The median dura-
tion of follow-up in survivors was 25 months (range, 19.3 to
48.5).
Feasibility and Safety
Twenty-two participants were evaluable for toxicity.
Eleven (50%) received an initial prednisone dose ofw.5 mg/
kg/day, 3 (14%) received an initial prednisone dose
of w.75 mg/kg/day, and 8 participants (36%) received an
initial prednisone dose of w1 mg/kg/day. One participant
was withdrawn from the study with primary coccidiomy-
cosis from an environmental exposure during cycle 1 of
Table 1
Baseline Characteristics of the Participants
Baseline Characteristics Value
Participants enrolled 22
Participants evaluable for response 20 (90.9)
Age, median (range), yr 51 (25-69)
Male 10 (45.5)
Primary diagnosis
AML 9 (40.9)
CLL, SLL, PLL 1 (4.5)
Hodgkin’s lymphoma 1 (4.5)
ALL 3 (13.6)
MDS 1 (4.5)
MPD 2 (9)
Mixed MDS/MPD 1 (4.5)
NHL 4 (18.2)
Stem cell source
PBSC 22 (100)
Donor source
8/8 MUD 13 (59.1)
8/8 MRD 5 (22.7)
7/8 MMUD 4 (18.2)
Patient-donor gender
F-F 5 (22.7)
F-M 7 (31.8)
M-F 1 (4.5)
M-M 9 (40.9)
Prior acute GVHD
Grade II-IV 3 (13.6)
Grade 0-I 19 (86.4)
Platelets, median (range),  109/L 197 (90-378)
Days after HSCT to cGVHD onset, median (range) 215 (133-666)
Days after HSCT to initiation of cGVHD therapy,
median (range)
257 (186-2070)
Concurrent agents
Tacrolimus 6 (27.3)
Sirolimus 3 (13.6)
Mycophenolate mofetil 1 (4.5)
AML indicates acute myeloid leukemia; CLL, chronic lymphocytic leukemia;
SLL, small lymphocytic leukemia; PLL, prolymphocytic leukemia; ALL, acute
lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPD, myelo-
proliferative disorder; NHL, non-Hodgkin lymphoma; PBSC, peripheral
blood stem cells; MUD, matched unrelated donor; MRD, matched related
donor; MMUD, mismatched unrelated donor; F, female; M, male.
Data presented are n (%) unless otherwise indicated.
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leukemia during cycle 2dboth deemed unrelated to borte-
zomib. One participant developed grade 3 Common Termi-
nology Criteria for Adverse Events v3.0 sensory neuropathy,
possibly related to bortezomib. There were no other grade
3 adverse events probably or possibly related to bortezo-
mib. Eighteen participants (82%) completed all 3 cycles of
combination therapy.
Clinical Response
Twenty participants were evaluable for response and 16
(80%) exhibited an objective response after 15 weeks per NIH
consensus response criteria. Two (10%) had a CR and 14 par-
ticipants (70%) had a PR to study treatment. One participant
(5%) had SD. One participant (5%) had a mixed response, with
complete resolution of cGVHD in sites of severe involvement
(liver and skin), but interval progression of bronchiolitis
obliterans (BO). Two participants (10%), both with liver
involvement, had progressive cGVHD with rising trans-
aminases on days 11 and 15 after treatment initiation,
respectively, forwhichan increasedprednisonedoseabove the
initial .5 mg/kg daily was required. There was no association
betweendaily prednisone dose and response,with themedian
initial prednisonedose in responders (CR/PR) at .73mg/kg/day
compared with .54 mg/kg/day in nonresponders (mixedresponse/SD/PD) (P ¼ .28). The single participant (100%) with
mild cGVHD, 5 of 6 participants (83%) with moderate cGVHD,
and 10 of 13 participants (77%) with severe cGVHD, per NIH
global score criteria, had objective evidence of response. Both
participants achieving CR had severe cGVHD at baseline
without ﬁxed, “irreversible” manifestations of cGVHD (see
Supplementary Table A and B for details).
Responses by evaluable organ site included skin (n ¼ 11):
8 (73%) CR, 1 (9%) PR, and 2 (18%) SD; liver (n ¼ 15): 8 (53%)
CR, 5 (33%) PR, and 2 (13%) participants with progressive liver
cGVHD; gastrointestinal (GI) tract (n ¼ 8): 6 (75%) CR, 1
(12.5%) PR, and 1 (12.5%) SD; joint, muscle, or fascia
involvement (n ¼ 6): 2 (33%) CR, 1 (17%) PR, and 3 (50%) SD;
and lung (n ¼ 3): 1 (33%) CR, 1 (33%) SD, and 1 (33%)
participant with progressive BO. Clinically, the participant’s
course was consistent with steady progression of BO/cGVHD,
despite study treatment, but the potential of pulmonary
toxicity associated with bortezomib cannot be excluded. The
3 participants (100%) with severe skin cGVHD had complete
resolution of skin cGVHD. All participants (n ¼ 7) with ery-
thema, pruritis, and maculopapular rash (range, 7% to 90%
body surface area involved) as predominant skin GVHD
manifestations had complete resolution of their skin GVHD.
Four evaluable participants had lichen planus or sclerotic
skin cGVHD, with 2 exhibiting stability of these skin cGVHD
manifestations,1 participant with a PR, and 1 participant had
resolution of moderate severity sclerotic skin cGVHD. Five of
11 participants (45%) with severe liver cGVHD had complete
resolution of liver cGVHD. Responses included improvement
in all liver function tests, including transaminases, alkaline
phosphatase, and bilirubin. Participants with GI cGVHD pri-
marily had upper GI manifestations, and responses included
resolution or improvement of dysphagia, esophagitis, and
nausea. Participants with musculoskeletal involvement all
had fasciitis without joint contractures, and responses
included softening of fasciitis with improvement in range of
motion. Responses in each participant by speciﬁc organ site,
including organ-site severity, and the median cGVHD global
and NIH cGVHD organ-site scores in the cohort at baseline
and week 15 are detailed in Figure 1.
Fourteen participants (70%) tolerated a 50% steroid dose
reduction by week 15. The median prednisone dose of the
cohort decreased from 50mg (range, 30 to 100) at baseline to
20 mg (range, 5 to 40) at week 15 (P< .001). The end of study
failure-free survival at 15 weeks in the entire cohort (n ¼ 22)
was 82%. One year after completing study treatment, 5 (25%)
evaluable participants were off prednisone completely, 2
(10%) participants were receiving less than .25 mg/kg daily of
prednisone, 10 (50%) participants required additional cGVHD
therapy, 1 participant died of relapsed acute lymphoblastic
leukemia, and 1 participant died of autopsy-proven pulmo-
nary veno-occlusive disease (Figure 2).
The 2-year OS and RFS were both 73% in the cohort
(n ¼ 22) and the cumulative incidence of NRM and relapse
were 14% each for the entire cohort (Figure 3). For responders
(n¼ 16), the 2-year OS and RFS were 88% and the cumulative
incidence of NRM and relapse were 6.3% each.
Laboratory and Correlative Analyses
Fifteen weeks of bortezomib and prednisone therapy did
not induce clinically signiﬁcant leukopenia, anemia, or
thrombocytopenia. The median peripheral blood total
lymphocyte, total T cell, and CD8þ T cell counts in the cohort
declined after 15 weeks of study therapy (all P¼ .04). Median
peripheral blood B cell counts were unaffected by
Figure 1. Heat map depicting baseline chronic GVHD involvement by organ site and week 15 response at all evaluable sites. Global and organ site chronic GVHD
responses at week 15 (right panel) in each evaluable participant at each site of cGVHD involvement compared with baseline involvement (left panel), scored ac-
cording to NIH consensus criteria. Two participants had early progression of liver cGVHD and came off study before week 15, liver organ scores at study withdrawal
are included. Median provider-reported global cGVHD scores and NIH organ-site cGVHD scores at baseline and week 15 are included. Asterisk denotes statistically
signiﬁcant difference between baseline and week 15 (all P  .02).
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counts initially declined but were not reduced compared
with baseline at 15 weeks (Figure 4A). The median total Treg
count and Treg to Tcon ratio at baseline were 39.5 cells/mm3
and .15, respectively, and declined after 15 weeks of borte-
zomib and prednisone to 20.8 cells/mm3 (P < .0001) and .08
(P ¼ .0002), respectively (Figure 4B). The median memory
Treg count was decreased at 15 weeks compared with
baseline (P < .0001). However, the median naïve Treg count
was not signiﬁcantly affected at 15 weeks (P ¼ .12)
(Figure 4C). Median total DC, myeloid DC, and plasmacytoid
DC counts were decreased at 15 weeks compared with
baseline (P¼ .039, P¼ .011, P¼ .005, respectively) (Figure 4D).Figure 2. Prednisone dose and additional cGVHD therapy over time. Prednisone dose
after the completion of bortezomib therapy, and 1 year after the completion of bortezo
n ¼ 22, n ¼ 22, n ¼ 18, n ¼ 17, respectively. (B) Shows the prednisone dose and addTotal lymphocytes, total and CD8 þ T cells, total and memory
Tregs, and total and subset DC counts recovered to baseline
by 3 months after the last bortezomib dose.
DISCUSSION
Chronic GVHD is an important source of morbidity and
mortality after allogeneic HSCT with limited treatment op-
tions. Corticosteroids are the mainstay of upfront therapy
and efforts to improve cGVHD outcomes by adding other
agents, such as thalidomide or mycophenolate mofetil, have
been unsuccessful [27-29]. Bortezomib is a proteasome in-
hibitor with immunomodulatory effects that we hypothe-
sized may be useful in treating cGVHD.at baseline, study week 15 (the completion of bortezomib therapy), 3 months
mib therapy. (A) Shows median prednisone dose in the cohort over time, Note:
itional cGVHD therapy in each participant over time.
Figure 3. Kaplan-Meier analysis of overall survival and relapse-free survival in
the cohort over time.
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receiving recent systemic glucocorticoid therapy, the study
cohort was primarily composed of participants with de novo
cGVHD, with some participants exhibiting quiescent cGVHD.
There were no patients with progressive cGVHD. This pro-
portion of de novo cGVHD is in line with practice patterns at
our center.Figure 4. Immune correlates. (A) Shows median peripheral blood T, B, NK lymphocyte
and Treg to Tcon ratio. (C) Shows median peripheral blood regulatory T cell subset c
counts on bortezomib and prednisone therapy. For all analyses, n ¼ 21 at baseline; n ¼
initial bortezomib dose. Cell counts were compared between time points using the
change at a time point compared with baseline.In our study, the addition of 15 weeks of bortezomib to
prednisone for the initial treatment of cGVHD was feasible
and well tolerated. Toxicity was minimal, with only 1 occur-
rence of grade 3 sensory peripheral neuropathy possibly
related to bortezomib. There were no grade 3 infectious or
other adverse events related to study treatment (see
Supplementary Table B for list of grade 3 adverse events).
The response rate was high at 15 weeksdthe completion
of study treatment. In particular, liver cGVHD and erythem-
atous or maculopapular skin GVHD appeared sensitive to
combined bortezomib and prednisone therapy, despite se-
vere baseline organ involvement. As a study of initial therapy
for incident cGVHD, we had few participants with lichen
planus-like or sclerotic skin cGVHD. The median corticoste-
roid dose at 15 weeks in the cohort decreased substantially,
suggesting that bortezomibmayoffer steroid-sparing efﬁcacy
in cGVHD therapy.
The required weekly bortezomib infusions were a barrier
to accrual and selected for a study population with severe
cGVHD. For instance, 50% of our participants had severe liver
cGVHD and 64% had severe global cGVHD per the NIH scale,
as compared with 1% severe liver cGVHD and 4% severe
global cGVHD in the prednisone-only control arm of a ran-
domized upfront cGVHD treatment study [28]. Therefore,
although response rates in our cohort appear comparablelineage counts. (B) Shows median peripheral blood total regulatory T cell count
ounts. (D) Shows median peripheral blood total and dendritic cell subset cell
18 at week 6, n ¼ 19 at week 11, n ¼ 19 at week 15, and n ¼ 10 at 6 months after
Wilcoxon signed-rank test. Asterisk denotes statistically signiﬁcant (P  .05)
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trials [28,30], we could not identify an appropriate clinical
comparator cohort in the literature.
In our study, immunophenotypic analyses indicated that
the bortezomib and prednisone combination reduced in vivo
peripheral blood DC counts throughout the study period.
Although previous reports suggested Treg survival was un-
affected by bortezomib, the median total Treg count and the
Treg to Tcon ratio declined in our study during the 15 weeks
of bortezomib and prednisone therapy [12,17]. Naïve Tregs
remained stable. This may be of interest, as there is evidence
suggesting that naïve Tregs may help control GVHD and that
severe cGVHD is associatedwith a naive Treg deﬁcit [31,32]. B
cells, also implicated in the pathogenesis of cGVHD, were
unaffected [33-40]. As therewas only 1male participant with
a female donor, we were unable to evaluate treatment
impact on allo-reactive H-Y antibodies. Although potentially
interesting as biomarkers of response, these ﬁndings may
reﬂect the impaired immune reconstitution and Treg deﬁcit
observed in severe cGVHD [31,41,42]. We further invoke
caution, as it is not possible to isolate the impact of borte-
zomib in this study of combination therapy, and our ﬁndings
may represent the effect of corticosteroids.
In this study, bortezomib therapy was discontinued after
15 weeks. Hence, we reported failure-free survival at
15 weeks. Classifying cGVHD progression after the discon-
tinuation of bortezomib therapy as a treatment failure would
imply that bortezomib has sustained, long-term immuno-
modulatory effects in cGVHD, which has not been demon-
strated. Within 3 months of bortezomib discontinuation,
corticosteroid taper continued in the majority of partici-
pants, but many developed progressive cGVHD that required
additional therapy. This may be due to the severity of base-
line cGVHD involvement in the cohort. It also suggests that
any beneﬁt conferred by the addition of bortezomib
to corticosteroids may require continued bortezomib expo-
sure. Indeed, other immunomodulatory therapies for cGVHD,
such as low-dose interleukin-2, have resulted in durable
responses with continued administration [43]. However,
long-term bortezomib therapy early after allogeneic HSCT
has been associated with neurologic, gastrointestinal, and
hematologic toxicities [22,44,45]. Consideration of mainte-
nance bortezomib for cGVHD therapy would require
weighing the adverse effects against any potential beneﬁts
in a clinical trial. This issue and accrual challenges may be
circumvented in future studies by using oral proteasome-
inhibitors. These newer agents are associated with less
neurotoxicity, which may evade another obstacle to long-
term proteasome-inhibitor use.
Although the cGVHD responses in this study are encour-
aging, the lack of a comparator arm precludes a deﬁnitive
determination of the impact of adding bortezomib to pred-
nisone for initial therapy of cGVHD. Previous studies of initial
cGVHD therapy have demonstrated high response rates in
corticosteroid-alone control arms, and it remains possiblewe
may have observed similar responses with single-agent
corticosteroid therapy if our trial had a control arm. A ran-
domized study would be necessary to determine whether
proteasome inhibition confers a beneﬁt in this setting. We
caution against the use of bortezomib or other proteasome
inhibitors for the treatment of cGVHD outside of the setting
of a clinical trial. However, our phase II results indicate that
study of proteasome inhibitors for treatment of cGVHD is of
interest, and further exploration of proteasome inhibition
(eg, different agents, route of administration, or dosingschedule) alone or in combination with other cGVHD treat-
ments may be worthwhile.
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